Indirect comparison of the cost-effectiveness of letrozole plus lapatinib (LET plus LAP) versus anastrozole plus trastuzumab (ANA plus TZ) as first-line treatment for postmenopausal women with HER2+and HR+ metastatic breast cancer (MBC) from the UK National Health Service (NHS) perspective

被引：1
|
作者：
Hastings, V.
Delea, T. E.
Amonkar, M.
Lykopoulos, K.
Diaz, J.
Johnston, S. R.
机构：
[1] Policy Anal Inc, Brookline, MA USA
[2] GlaxoSmithKline, Collegeville, PA USA
[3] GlaxoSmithKline Global Hlth Outcomes, London, England
[4] GlaxoSmithKline Hllth Outcomes Oncol, London, England
[5] Royal Marsden NHS Fdn Trust, Inst Canc Res, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.1035
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1035
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Cost-Effectiveness Analysis of Abemaciclib Plus Fulvestrant in the Second-Line Treatment of Women With HR+/HER2-Advanced or Metastatic Breast Cancer: A US Payer Perspective
    Wang, Yingcheng
    Rui, Mingjun
    Guan, Xin
    Cao, Yingdan
    Chen, Pingyu
    FRONTIERS IN MEDICINE, 2021, 8
  • [22] COST-EFFECTIVENESS OF FIRST-LINE COMBINATION TREATMENT WITH BEVACIZUMAB PLUS FOLFIRI VERSUS FOLFIRI IN PATIENTS WITH METASTATIC COLORECTAL CANCER: A UK PERSPECTIVE
    Gyldmark, M.
    Aultman, R.
    Siebert, U.
    Sabate, E.
    VALUE IN HEALTH, 2009, 12 (03) : A49 - A49
  • [23] An evaluation of the clinical and cost-effectiveness of combination chemotherapy with gemcitabine plus paclitaxel for the treatment of metastatic breast cancer (MBC) in the UK from an NHS perspective.
    Bhalla, S.
    Hibbert, C.
    Chetty, M.
    Poole, C.
    Miles, D.
    Coleman, R.
    Bruce, G.
    Beard, S.
    Watkins, J.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S232 - S232
  • [24] Cost-Effectiveness of Pyrotinib Plus Capecitabine versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer in China: A Scenario Analysis of Health Insurance Coverage
    Bao, Yuwen
    Zhang, Zhuolin
    He, Xuan
    Cai, Lele
    Wang, Xiao
    Li, Xin
    CURRENT ONCOLOGY, 2022, 29 (09) : 6053 - 6067
  • [25] First-line ribociclib plus letrozole for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-), advanced breast cancer (ABC)
    Hortobagyi, G. N.
    Stemmer, S. M.
    Burris, H. A.
    Yap, Y. S.
    Sonke, G. S.
    Paluch-Shimon, S.
    Campone, M.
    Blackwell, K.
    Andre, F.
    Winer, E. P.
    Janni, W.
    Verma, S.
    Conte, P.
    Arteaga, C. L.
    Cameron, D.
    Xuan, F.
    Souami, F.
    Miller, M.
    Germa, C.
    O'Shaughnessy, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [26] MONARCH 3: A randomized phase III study of anastrozole or letrozole plus abemaciclib, a CDK4/6 inhibitor, or placebo in first-line treatment of women with HR+, HER2-locoregionally recurrent or metastatic breast cancer (MBC).
    Goetz, Matthew P.
    Toi, Masakazu
    Klise, Suzanne
    Frenzel, Martin
    Bourayou, Nawel
    Di Leo, Angelo
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [27] A cost-effectiveness analysis of palbociclib plus letrozole as first-line treatment for estrogen receptor-positive, HER2-negative, metastatic breast cancer.
    Matter-Walstra, Klazien
    Schwenkglenks, Matthias
    Brauchli, Peter
    Klingbiel, Dirk
    Dedes, Konstantin J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [28] COST-EFFECTIVENESS OF ALPELISIB PLUS FULVESTRANT FOR THE TREATMENT OF POSTMENOPAUSAL WOMEN WITH PIK3CA MUTANT, HR+/HER2-ADVANCED BREAST CANCER IN TURKEY
    Tatar, M.
    Akgul, T.
    Ozbalas, T.
    Yuzgenc, Z.
    Cilingiroglu, M.
    VALUE IN HEALTH, 2022, 25 (12) : S133 - S133
  • [29] Cost-effectiveness analysis of anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with hormone receptor-positive (HR+) advanced breast cancer (ABC): a UK perspective
    Simons, R
    Bassi, R
    Jones, D
    Barrett-Lee, P
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S68 - S68
  • [30] Cost-effectiveness of CDK4/6 inhibitors in the first-line treatment of HR+/HER2-metastatic breast cancer in postmenopausal women in Panama
    Castillo-Fernandez, Omar O.
    Lim, Maria
    Montano, Lilian
    CANCER RESEARCH, 2023, 83 (05)
12345